Program: Oral and Poster Abstracts
Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III
METHODS: A case control study included 134 ALL&AML cases& 134 matched controls for age &sex from the same family relatives to evaluate socioeconomic &genetic causes of the disease. The mothers were interviewed for the completion of interview format that included: duration & patterns of breastfeeding.
RESULTS: lower proportion of acute leukemia cases 59.7% were exclusively breast-fed babies as compared to 89.6% of the control subjects. However, higher proportions of index children were either predominant breast-fed 19.4% or complementary-fed 10.4%. Nearly 10.4% were bottle-fed babies as compared to none of their controls. The differences between cases & controls as regards pattern of breast feeding were statistically significant where p <0.001. As regards duration of breastfeeding 75.4% of index children were breast-fed for more than 6 months as compared to vast majority of their controls (97.8%). The difference between cases & controls was statistically significant where p <0.001. The association also was statistically significant when 2 groups (standard &high risk) were considered as regards pattern of breastfeeding where x2=13.055, p =0.004. The multivariate logistic regression analysis indicated that bottle feeding had the odds of 7.76 of being at high risk level for acute leukemia (OR=7.76, 95% CI 1.9-33.8).
CONCLUSION: Exclusive breast-feeding and breast-feeding for one year are protective against acute childhood leukemia.
Table 1: Bivariate and multivariate analysis for pattern & duration of breastfeeding of the studied children with acute leukemia and their controls.
Pattern and duration of breastfeeding |
Bi variant variable |
Multivariate variable |
||||||
Type of feeding during the first 6 month of life. |
Cases (n=134) |
Control (n=134) |
Significance |
OR |
(95% CI) |
Significance |
||
No. |
% |
No. |
% |
X2 = 37.6 P>0.0001* |
1 |
|||
Exclusive BF |
80 |
59.7 |
120 |
89.6 |
||||
Predominant BF |
26 |
19.4 |
13 |
9.7 |
1.67 |
(1.26 – 2.2)* |
X2 = 9.4 P=0.002* |
|
Complementary feeding |
14 |
10.4 |
1 |
0.7 |
21 |
(2.8 – 436.4)* |
X2 = 16.13 P>0.0001* |
|
Bottle feeding |
14 |
10.4 |
0 |
0 |
2.5 |
(2.1 – 2.9)* |
X2 = 19.12 P>0.0001* |
|
Duration of breastfeeding |
|
|
|
|||||
0-≤ 3 month |
2 |
1.7 |
0 |
0 |
X2=15.331 MCP=0.0001* |
AN- |
FEP=0.18 =13.06 P=0.0003*
X2=0.38 P=0.537 |
|
3-≤ 6 month |
17 |
14.2 |
3 |
2.2 |
7.6 |
(2.1 – 33.8)* |
||
6-12 month |
16 |
13.3 |
17 |
12.7 |
1.26 |
0.6-2.8 |
||
More than 12 month |
85 |
70.8 |
114 |
85.1 |
1 |
- |
X2: Chi-Square test FEP: Fisher’s Exact test -NA-: Not Applicable *significant at P≤0.0
Disclosures: Hassab: Eli Lilly and Company: Research Funding .
See more of: Acute Lymphoblastic Leukemia: Clinical Studies
See more of: Oral and Poster Abstracts
*signifies non-member of ASH